Wassim Kassouf Selected Research

Cystectomy

10/2022	Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.
6/2022	Role of prehabilitation following major uro-oncologic surgery: a narrative review.
6/2022	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.
2/2022	Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.
1/2022	Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer.
1/2022	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.
2/2021	Postoperative ileus: A systematic pathway for radical cystectomy candidates?
1/2021	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
1/2021	Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis.
1/2021	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wassim Kassouf Research Topics

Disease

108	Urinary Bladder Neoplasms (Bladder Cancer) 10/2022 - 12/2004
85	Neoplasms (Cancer) 10/2022 - 05/2003
84	Carcinoma (Carcinomatosis) 01/2022 - 06/2006
17	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 05/2003
14	Neoplasm Metastasis (Metastasis) 11/2015 - 02/2004
12	Non-Muscle Invasive Bladder Neoplasms 10/2022 - 12/2009
11	Renal Cell Carcinoma (Grawitz Tumor) 06/2019 - 05/2007
10	Carcinoma in Situ 01/2019 - 06/2006
8	Margins of Excision 01/2019 - 01/2009
4	Hernia (Hernias) 10/2022 - 08/2005
4	Hydronephrosis 01/2021 - 05/2011
4	Disease Progression 08/2018 - 05/2007
4	Lymphatic Metastasis 01/2013 - 02/2004
3	Pathologic Constriction (Stenosis) 10/2022 - 01/2010
3	Adenocarcinoma 01/2020 - 03/2014
3	Carcinogenesis 11/2015 - 04/2009
2	Obesity 01/2022 - 02/2013
2	Hypertension (High Blood Pressure) 01/2022 - 08/2019
2	Ileus 02/2021 - 12/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 01/2020
2	Kidney Neoplasms (Kidney Cancer) 06/2019 - 06/2018
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 04/2012 - 01/2007
2	Extranodal Extension 03/2012 - 10/2006
2	Necrosis 11/2010 - 04/2010
2	Hematuria 04/2009 - 06/2008
2	Transitional Cell Carcinoma 08/2007 - 03/2006
1	Ureteral Obstruction 10/2022
1	Hypertriglyceridemia 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Sarcopenia 01/2022
1	Neuroendocrine Carcinoma 01/2021
1	Convalescence 08/2020
1	Asymptomatic Diseases 03/2020
1	Small Cell Carcinoma 01/2020
1	Coronary Artery Disease (Coronary Atherosclerosis) 08/2019
1	Ureteral Neoplasms (Ureteral Cancer) 09/2017
1	Body Weight (Weight, Body) 11/2014

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 02/2022 - 06/2008
6	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 06/2009
6	Biological ProductsIBA 03/2017 - 09/2008
5	ErbB Receptors (EGF Receptor)IBA 02/2011 - 11/2005
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2006
4	Gemcitabine FDA Link 01/2018 - 10/2006
4	Gefitinib (Iressa)FDA Link 01/2013 - 11/2005
4	Pharmaceutical PreparationsIBA 09/2010 - 08/2006
3	HMGB1 Protein (HMG1)IBA 01/2021 - 03/2016
3	Prostate-Specific Antigen (Semenogelase)IBA 08/2019 - 05/2003
3	Everolimus FDA Link 04/2017 - 12/2009
3	Indicators and Reagents (Reagents)IBA 10/2013 - 04/2010
3	PPAR gammaIBA 01/2013 - 01/2006
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2008 - 02/2004
2	AndrogensIBA 01/2022 - 05/2003
2	Testosterone (Sustanon)FDA Link 01/2022 - 08/2018
2	atezolizumabIBA 12/2021 - 01/2021
2	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2020
2	B7-H1 AntigenIBA 01/2021 - 08/2020
2	Docetaxel (Taxotere)FDA Link 03/2020 - 08/2006
2	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 02/2015
2	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018 - 02/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 02/2015
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 08/2014 - 09/2010
2	TOR Serine-Threonine KinasesIBA 09/2013 - 12/2009
2	Tumor Biomarkers (Tumor Markers)IBA 11/2010 - 04/2007
2	nuclear matrix protein 22IBA 12/2009 - 06/2008
2	Tyrosine Kinase InhibitorsIBA 08/2009 - 11/2005
2	LigandsIBA 04/2009 - 05/2005
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	HDL CholesterolIBA 01/2022
1	NivolumabIBA 12/2021
1	5-alpha Reductase InhibitorsIBA 01/2021
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2021
1	TEMPOIBA 10/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 08/2020
1	NectinsIBA 08/2020
1	Interleukin-13IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2018
1	5-aminolevulinic acid hexyl ester FDA Link 06/2017
1	BCG Vaccine FDA Link 12/2016

Therapy/Procedure

103	Cystectomy 10/2022 - 03/2006
56	Therapeutics 10/2022 - 05/2003
40	Nephroureterectomy 08/2020 - 02/2009
29	Drug Therapy (Chemotherapy) 02/2022 - 10/2006
27	Neoadjuvant Therapy 06/2022 - 07/2007
27	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 01/2007
24	Adjuvant Chemotherapy 01/2020 - 01/2008
11	Radiotherapy 02/2022 - 03/2012
9	Nephrectomy 06/2019 - 05/2007
6	Prostatectomy (Retropubic Prostatectomy) 06/2022 - 07/2007
5	Immunotherapy 05/2021 - 12/2004
4	Castration 01/2022 - 07/2013
4	Urinary Diversion (Ileal Conduit) 11/2019 - 01/2010
3	Transurethral Resection of Bladder 01/2022 - 06/2017
2	Preoperative Exercise 06/2022 - 11/2014
2	Aftercare (After-Treatment) 01/2020 - 08/2018
1	Immunomodulation 05/2021
1	Activities of Daily Living (ADL) 01/2021
1	Length of Stay 08/2020
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Continuity of Patient Care 01/2017
1	Combined Modality Therapy 12/2016